PRELIMINARY RESULT OF MIXED BACTERIAL VACCINE AS ADJUVANT TREATMENT OF HEPATOCELLULAR-CARCINOMA

被引：2

作者：

TANG, ZY ^{[1
]}

ZHOU, HY ^{[1
]}

ZHAO, G ^{[1
]}

CHAI, LM ^{[1
]}

ZHOU, M ^{[1
]}

LU, JZ ^{[1
]}

LIU, KD ^{[1
]}

HAVAS, HF ^{[1
]}

NAUTS, HC ^{[1
]}

机构：

[1] SHANGHAI MED UNIV,ZHONG SHAN HOSP,INST LIVER CANC,SHANGHAI,PEOPLES R CHINA

来源：

MEDICAL ONCOLOGY AND TUMOR PHARMACOTHERAPY | 1991年 / 8卷 / 01期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Mixed bacterial vaccine (MBV) was employed in the multi-modality treatment of hepatocellular carcinoma (HCC) during 1985-1988. Thirty eight patients undergoing palliative resection and cisplatin therapy (Series 1) and 48 patients with unresectable HCC who received hepatic artery ligation + intraarterial cisplatin infusion + radiotherapy (Series 2) were randomized to receive MBV or not. In series 1, the 1- and 2-year survival rates of MBV group and control were 75% vs 58% (P = 0.19) and 45% vs 39% (P = 0.23). In series 2, the 1-, 2- and 3-year survival rates were 59%, 41% and 41% for MBV group and 39%, 25% and 20% for the control, respectively (P1 = 0.07, P2 = 0.09, P3 = 0.07). In addition, MBV improved the "second look" resection rate to 40% as compared to 17% in the control (P > 0.05). MBV could also prevent such immunosuppression as decrease of macrophage activity caused by radiotherapy. We consider MBV a potential nonspecific immunostimulant in the multimodality treatment of HCC.

引用

页码：23 / 28

页数：6